Upvote Story 17

Hypothermia in Sepsis – The CASS Trial

Hypothermia in Sepsis – The CASS Trial

Sepsis and especially septic shock (no matter what definition you use) is a recipe for multi-organ dysfunction and poor prognosis. In the past few years, we saw a lot of failed attempts trying to find something that could decrease sepsis mortality. From immunoglobulin to recombinant activated protein C, and of course Marik’s elixir (hydrocortisone, vitamin C, and thiamine). Well, the later is an unproven intervention, while the first didn’t work, and the second was withdrawal from the market. Our friends from the North designed a multicenter, randomized, controlled trial. From 2011 to 2016, they recruited ICU patients with severe sepsis or septic shock (remember the new sepsis definitions only came to life two years ago), ≥50y/o (including older patients would increase the study power) who were mechanically ventilated.

CriticalCare.news
January 17, 2018

Leave Your Comment